Business
PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*
LANGHORNE, Pa., January 08, 2026--PANTHERx® Rare Pharmacy, the trusted leader and innovator in patient access and support services for personalized rare disease care, and Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced an exclusive distribution agreement for MOLBREEVI. Savara submitted the MOLBREEVI BLA to the U.S. Food and Drug Administration (FDA) in December 2025 for the treatment of autoimmune PAP. Priority Review was req
About this update from Savara, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/7182b05e7240fe1f4bbd7a0f2a8ca7fe"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/XGoWifjcO.XLOqo3278GEQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/7182b05e7240fe1f4bbd7a0f2a8ca7fe","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/AWPM1rT.b1dNE0ZLiL8L9w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/7182b05e7240fe1f4bbd7a0f2a8ca7fe","width":1024,"height":512}},"lazy":false},{"type":"text","content":"--Savara Submitted the MOLBREEVI Biologics License Application (BLA) in December 2025 for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)--","length":177,"tagName":"p","attribs":{}},{"type":"text","content":"LANGHORNE, Pa., January 08, 2026--(BUSINESS WIRE)--PANTHERx® Rare Pharmacy, the trusted leader and innovator in patient access and support services for personalized rare disease care, and Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced an exclusive distribution agreement for MOLBREEVI. Savara submitted the MOLBREEVI BLA to the U.S. Food and Drug Administration (FDA) in December 2025 for the treatment of autoimmune PAP. Priority Review was requested.","length":524,"tagName":"p"},{"type":"text","content":"If approved, PANTHERx and its team of rare care experts will be responsible for the dispensing and distribution of MOLBREEVI in the U.S and will leverage its proprietary RxARECARE® model to deliver highly specialized rare disease patient and prescriber support services, including clinical case management, disease and therapy education, and comprehensive financial and insurance assistance.","length":391,"tagName":"p"},{"type":"text","content":""Our selection of PANTHERx as the exclusive U.S. specialty pharmacy for MOLBREEVI underscores Savara’s commitment to delivering more than a medicine—we will be delivering a complete care experience for patients," said Braden Parker, Chief Commercial Officer, Savara. "This partnership reflects our shared mission to improve the lives of p...